Comparative Pharmacology
Head-to-head clinical analysis: MYCHEL S versus NITROFURANTOIN MACROCRYSTALLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCHEL S versus NITROFURANTOIN MACROCRYSTALLINE.
MYCHEL-S vs NITROFURANTOIN MACROCRYSTALLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulconazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit multiple bacterial enzymes involved in carbohydrate metabolism, including acetyl-CoA synthetase, and disrupt cell wall synthesis.
200 mg orally every 12 hours for 14 days
100 mg orally twice daily for 5-7 days (uncomplicated UTI); 100 mg orally every 12 hours for 10-14 days (pyelonephritis: not first-line).
None Documented
None Documented
3-4 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Terminal half-life: 20-60 minutes (short, requires q6h dosing for therapeutic efficacy).
Renal: 70-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Renal: 30-40% excreted unchanged in urine. Biliary/fecal: minimal; remainder metabolized or eliminated via other routes.
Category C
Category D/X
Antibiotic
Antibiotic